These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

292 related items for PubMed ID: 27027438

  • 1. BM microenvironmental protection of CML cells from imatinib through Stat5/NF-κB signaling and reversal by Wogonin.
    Xu X, Zhang X, Liu Y, Yang L, Huang S, Lu L, Wang S, Guo Q, Zhao L.
    Oncotarget; 2016 Apr 26; 7(17):24436-54. PubMed ID: 27027438
    [Abstract] [Full Text] [Related]

  • 2. Bone marrow microenvironment confers imatinib resistance to chronic myelogenous leukemia and oroxylin A reverses the resistance by suppressing Stat3 pathway.
    Li X, Miao H, Zhang Y, Li W, Li Z, Zhou Y, Zhao L, Guo Q.
    Arch Toxicol; 2015 Jan 26; 89(1):121-36. PubMed ID: 24671465
    [Abstract] [Full Text] [Related]

  • 3. Oroxylin A reverses the drug resistance of chronic myelogenous leukemia cells to imatinib through CXCL12/CXCR7 axis in bone marrow microenvironment.
    Li W, Ding Q, Ding Y, Lu L, Wang X, Zhang Y, Zhang X, Guo Q, Zhao L.
    Mol Carcinog; 2017 Mar 26; 56(3):863-876. PubMed ID: 27533597
    [Abstract] [Full Text] [Related]

  • 4. Bone marrow-derived mesenchymal stromal cells promote resistance to tyrosine kinase inhibitors in chronic myeloid leukemia via the IL-7/JAK1/STAT5 pathway.
    Zhang X, Tu H, Yang Y, Jiang X, Hu X, Luo Q, Li J.
    J Biol Chem; 2019 Aug 09; 294(32):12167-12179. PubMed ID: 31235520
    [Abstract] [Full Text] [Related]

  • 5. CM363, a novel naphthoquinone derivative which acts as multikinase modulator and overcomes imatinib resistance in chronic myelogenous leukemia.
    Guerra B, Martín-Rodríguez P, Díaz-Chico JC, McNaughton-Smith G, Jiménez-Alonso S, Hueso-Falcón I, Montero JC, Blanco R, León J, Rodríguez-González G, Estévez-Braun A, Pandiella A, Díaz-Chico BN, Fernández-Pérez L.
    Oncotarget; 2017 May 02; 8(18):29679-29698. PubMed ID: 27557509
    [Abstract] [Full Text] [Related]

  • 6. Wogonin reversed resistant human myelogenous leukemia cells via inhibiting Nrf2 signaling by Stat3/NF-κB inactivation.
    Xu X, Zhang X, Zhang Y, Yang L, Liu Y, Huang S, Lu L, Kong L, Li Z, Guo Q, Zhao L.
    Sci Rep; 2017 Feb 02; 7():39950. PubMed ID: 28150717
    [Abstract] [Full Text] [Related]

  • 7. Overexpression of Tpl2 is linked to imatinib resistance and activation of MEK-ERK and NF-κB pathways in a model of chronic myeloid leukemia.
    Chorzalska A, Ahsan N, Rao RSP, Roder K, Yu X, Morgan J, Tepper A, Hines S, Zhang P, Treaba DO, Zhao TC, Olszewski AJ, Reagan JL, Liang O, Gruppuso PA, Dubielecka PM.
    Mol Oncol; 2018 May 02; 12(5):630-647. PubMed ID: 29485707
    [Abstract] [Full Text] [Related]

  • 8. Targeting methyltransferase PRMT5 eliminates leukemia stem cells in chronic myelogenous leukemia.
    Jin Y, Zhou J, Xu F, Jin B, Cui L, Wang Y, Du X, Li J, Li P, Ren R, Pan J.
    J Clin Invest; 2016 Oct 03; 126(10):3961-3980. PubMed ID: 27643437
    [Abstract] [Full Text] [Related]

  • 9. Wogonin induces cell cycle arrest and erythroid differentiation in imatinib-resistant K562 cells and primary CML cells.
    Yang H, Hui H, Wang Q, Li H, Zhao K, Zhou Y, Zhu Y, Wang X, You Q, Guo Q, Lu N.
    Oncotarget; 2014 Sep 30; 5(18):8188-201. PubMed ID: 25149543
    [Abstract] [Full Text] [Related]

  • 10. Selective JAK2/ABL dual inhibition therapy effectively eliminates TKI-insensitive CML stem/progenitor cells.
    Lin H, Chen M, Rothe K, Lorenzi MV, Woolfson A, Jiang X.
    Oncotarget; 2014 Sep 30; 5(18):8637-50. PubMed ID: 25226617
    [Abstract] [Full Text] [Related]

  • 11. Cryptotanshinone suppresses key onco-proliferative and drug-resistant pathways of chronic myeloid leukemia by targeting STAT5 and STAT3 phosphorylation.
    Dong B, Liang Z, Chen Z, Li B, Zheng L, Yang J, Zhou H, Qu L.
    Sci China Life Sci; 2018 Sep 30; 61(9):999-1009. PubMed ID: 30054832
    [Abstract] [Full Text] [Related]

  • 12. The antiproliferation effect of berbamine on k562 resistant cells by inhibiting NF-kappaB pathway.
    Wei YL, Liang Y, Xu L, Zhao XY.
    Anat Rec (Hoboken); 2009 Jul 30; 292(7):945-50. PubMed ID: 19548306
    [Abstract] [Full Text] [Related]

  • 13. Emodin Inhibits Resistance to Imatinib by Downregulation of Bcr-Abl and STAT5 and Allosteric Inhibition in Chronic Myeloid Leukemia Cells.
    Wang XY, Sun GB, Wang YJ, Yan F.
    Biol Pharm Bull; 2020 Jul 30; 43(10):1526-1533. PubMed ID: 32999163
    [Abstract] [Full Text] [Related]

  • 14. Cysteine-rich protein 61 regulates the chemosensitivity of chronic myeloid leukemia to imatinib mesylate through the nuclear factor kappa B/Bcl-2 pathway.
    Song Y, Lin Q, Cai Z, Hao T, Zhang Y, Zhu X.
    Cancer Sci; 2019 Aug 30; 110(8):2421-2430. PubMed ID: 31145521
    [Abstract] [Full Text] [Related]

  • 15. Targeting Hedgehog signaling pathway and autophagy overcomes drug resistance of BCR-ABL-positive chronic myeloid leukemia.
    Zeng X, Zhao H, Li Y, Fan J, Sun Y, Wang S, Wang Z, Song P, Ju D.
    Autophagy; 2015 Aug 30; 11(2):355-72. PubMed ID: 25701353
    [Abstract] [Full Text] [Related]

  • 16. HS-543 induces apoptosis of Imatinib-resistant chronic myelogenous leukemia with T315I mutation.
    Kim SJ, Jung KH, Yan HH, Son MK, Fang Z, Ryu YL, Lee H, Lim JH, Suh JK, Kim J, Lee S, Hong S, Hong SS.
    Oncotarget; 2015 Jan 30; 6(3):1507-18. PubMed ID: 25483100
    [Abstract] [Full Text] [Related]

  • 17. Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.
    Fiskus W, Pranpat M, Balasis M, Bali P, Estrella V, Kumaraswamy S, Rao R, Rocha K, Herger B, Lee F, Richon V, Bhalla K.
    Clin Cancer Res; 2006 Oct 01; 12(19):5869-78. PubMed ID: 17020995
    [Abstract] [Full Text] [Related]

  • 18. Persistent STAT5-mediated ROS production and involvement of aberrant p53 apoptotic signaling in the resistance of chronic myeloid leukemia to imatinib.
    Cheng Y, Hao Y, Zhang A, Hu C, Jiang X, Wu Q, Xu X.
    Int J Mol Med; 2018 Jan 01; 41(1):455-463. PubMed ID: 29115375
    [Abstract] [Full Text] [Related]

  • 19. Divalproex sodium enhances the anti-leukemic effects of imatinib in chronic myeloid leukemia cells partly through SIRT1.
    Wang W, Zhang J, Li Y, Yang X, He Y, Li T, Ren F, Zhang J, Lin R.
    Cancer Lett; 2015 Jan 28; 356(2 Pt B):791-9. PubMed ID: 25449787
    [Abstract] [Full Text] [Related]

  • 20. De-regulated STAT5A/miR-202-5p/USP15/Caspase-6 regulatory axis suppresses CML cell apoptosis and contributes to Imatinib resistance.
    Nie ZY, Yao M, Yang Z, Yang L, Liu XJ, Yu J, Ma Y, Zhang N, Zhang XY, Liu MH, Jiang LL, Luo JM.
    J Exp Clin Cancer Res; 2020 Jan 17; 39(1):17. PubMed ID: 31952546
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.